Adebrelimab

Adebrelimab (SHR-1316) is Jiangsu Hengrui Pharmaceuticals' anti-PD-L1 monoclonal antibody, already approved in China for first-line extensive-stage small cell lung cancer (ES-SCLC) and now being tested across a wide swath of solid tumors [1]. The trial anchoring this node, NCT06737913 (HAIBrave-001), pairs adebrelimab with bevacizumab and hepatic arterial infusion (HAI) FOLFOX chemotherapy for advanced unresectable hepatocellular carcinoma (HCC) [5]. The broader story matters more than any single trial. Hengrui is running adebrelimab through triple-negative breast, esophageal, gastric, and liver combinations, betting that a domestic PD-L1 backbone can substitute for Keytruda in Chinese practice while establishing enough combination evidence to support future out-licensing conversations. No specific out-licensing deal for adebrelimab has been publicly disclosed to date.

Adebrelimag is not a novel compound. China's NMPA approved it in March 2023 for first-line ES-SCLC in combination with carboplatin and etoposide, based on the CAPSTONE-1 Phase 3 trial (Wang J et al., Lancet Oncology 2022) [4]. It has no FDA approval and no publicly disclosed US regulatory filings. The HCC study referenced here (NCT06737913, HAIBrave-001) is a multicenter, open-label, randomized Phase 2 trial run out of Sun Yat-sen University, initiated January 2025, with Hengrui as the drug developer [5]. In parallel, the broader adebrelimab program includes a Phase 3 study of trastuzumab rezetecan plus adebrelimab in residual triple-negative breast cancer (NCT07679360, targeting invasive disease-free survival) [2], a Phase 2 neoadjuvant esophageal squamous cell carcinoma study with famitinib and chemo (NCT07796113, unverified) [3], and Phase 2 protocols in TNBC brain metastases and HER2-positive gastric cancer (both PMIDs unverified) [6][7]. No FDA breakthrough, fast track, orphan, or accelerated approval designations are in place. Most large readouts fall in the 2026 to 2028 window.

PD-L1 is a protein many tumors display on their surface. Think of it as a 'don't attack me' badge. When a T cell (the immune system's assassin) checks the tumor via its PD-1 receptor and sees the PD-L1 badge, it stands down. Adebrelimab is an antibody that plugs the PD-L1 badge so T cells stop getting the stand-down signal and can attack [8]. The mechanism is exhaustively validated. Pembrolizumab (Merck's Keytruda, ~$29.5B in 2024 net sales) and atezolizumab (Roche's Tecentriq) work by blocking the same axis [9]. The scientific question is not whether PD-1/PD-L1 blockade helps. It is which tumor, which patient, and which combination. Only 20 to 40 percent of patients respond even in well-selected populations. Biomarkers like PD-L1 immunohistochemistry (staining tumor tissue for PD-L1 protein) and tumor mutational burden partly predict response but leave a lot unexplained. Open Targets ranks CD274 (the gene coding PD-L1) with strong evidence scores across non-small cell lung, small cell lung, Merkel cell, head and neck, and hepatocellular carcinoma, which is why adebrelimab is being pushed into all of these indications simultaneously. The specific triplet rationale in HCC is a prime-and-sustain hypothesis. Bevacizumab is an anti-VEGF antibody that cuts off tumor blood supply, but reducing the chaotic tumor vasculature also normalizes remaining vessels, which paradoxically improves immune cell trafficking into the tumor. HAI FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin, all delivered through a catheter in the hepatic artery to concentrate dose in the liver) kills tumor cells locally and releases tumor antigens, priming a fresh immune response. Adebrelimab then sustains that response by keeping PD-L1 blocked. The bet is that each component enables the others rather than adding independently.

NCT06737913 (HAIBrave-001) is a multicenter, open-label, randomized Phase 2 study led by Sun Yat-sen University evaluating adebrelimab plus bevacizumab plus HAI FOLFOX in advanced unresectable HCC, with adebrelimab delivered either intravenously or via hepatic arterial infusion (the randomization axis) [5]. Results will be benchmarked against the IMbrave150 primary analysis for first-line advanced HCC: 27.3 percent confirmed objective response rate (ORR, meaning tumors shrinking by at least 30 percent per RECIST 1.1 criteria) and 19.2 month median overall survival for atezolizumab plus bevacizumab [11]. Enrollment target and expected readout are not publicly disclosed in the registry entry as of this writing. The bigger Hengrui-linked studies are more informative for the asset. NCT07679360 (Phase 3 residual TNBC) is the most commercially meaningful trial in the program, using invasive disease-free survival (iDFS) as the primary endpoint. iDFS counts any invasive breast cancer recurrence or death from any cause as an event, and is the standard Phase 3 surrogate for long-term cure rate in early breast cancer [2]. Real-world ES-SCLC data continues to accumulate in Chinese cohorts [10, unverified PMID], and a peer-reviewed retrospective cohort of adebrelimab plus bevacizumab plus HAIC in advanced HCC has been published, providing a real-world efficacy anchor for the triplet concept [12].

Our model estimates a 4% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by its light or open-label blinding; it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk: the IMbrave150 benchmark of 27.3 percent confirmed ORR and 19.2 month median OS is now standard of care in first-line advanced HCC [11]. Beating that ceiling with adebrelimab plus bevacizumab plus HAI FOLFOX requires clear differentiation, not incremental gains. In ES-SCLC, the Cochrane 2026 network meta-analysis found adebrelimab plus platinum/etoposide reduced the hazard of death with a hazard ratio of 0.72 (95% CI 0.58 to 0.90) versus platinum/etoposide alone, comparable to durvalumab (HR 0.71) and slightly behind serplulimab (HR 0.63) [1]. This positions adebrelimab as a middle-of-the-pack PD-L1 in the ES-SCLC landscape rather than a differentiated leader. Safety risk: HAI FOLFOX drives significant hepatotoxicity and biliary complications in patients with baseline cirrhosis. PD-L1 blockade adds immune-mediated hepatitis risk on top. Bevacizumab adds GI perforation, bleeding, and variceal hemorrhage risk. Three-agent regimens in cirrhotic patients are hard to run safely at scale. Execution risk: Chinese academic sponsor, and data will not translate cleanly to FDA context without a bridging study or global Phase 3. Hengrui has commercial infrastructure in China but limited Western regulatory track record for adebrelimab specifically. Commercial risk: no US approval means no Western revenue stream. Inside China, adebrelimab competes with camrelizumab (also Hengrui, PD-1), tislelizumab (BeiGene), sintilimab (Innovent), and toripalimab (Junshi). NRDL (National Reimbursement Drug List, China's reimbursement formulary that drives volume in exchange for steep negotiated price cuts) pricing pressure compresses margins meaningfully.

Watch the broader program, not the HCC trial in isolation. The signal-worthy events are, in order: (1) readout of NCT07679360, the Phase 3 residual TNBC study with trastuzumab rezetecan and adebrelimab [2]. A positive iDFS result opens a real out-licensing thesis for a Chinese antibody-drug conjugate (ADC, an antibody chemically linked to a cytotoxic payload) plus immuno-oncology combination, and would reset how the West prices Hengrui's oncology stack. (2) Any Hengrui move to file adebrelimab with FDA. Unlikely near-term but would materially change the commercial thesis. (3) Real-world HCC data continues to accumulate for the adebrelimab plus bevacizumab plus HAIC triplet concept, with at least one peer-reviewed retrospective cohort already published [12]. NCT06737913 itself is unlikely to move the needle unless the confirmed ORR lands meaningfully above 40 percent with acceptable Grade 3+ hepatic toxicity. The Cochrane 2026 network meta-analysis has already priced adebrelimab into the ES-SCLC field as roughly durvalumab-equivalent on OS, so the ES-SCLC story is now about volume and NRDL price, not efficacy differentiation.